Oct. 28, 2024 — As cannabis is legalized and is more accessible in various forms across the country, there is increasing concern among health care providers about potential impact on children.

Masimo executives are back calling their consumer audio business Sound United, with a senior executive on a conference call ...

Apple and Masimo’s legal battle over the Apple Watch’s Blood Oxygen sensing feature continues this week as both firms meet in ...

Executives said the patient monitoring company’s consumer business will likely become a discontinued operation if it is not ...

Masimo delivered Q3 results that mostly aligned with guidance, yet it faces challenges in its non-healthcare segment.

Baxter will share an update on Hurricane Helene’s impact, while Medtronic will likely discuss a new pulsed field ablation ...

The consensus rating for Masimo is Buy, based on 2 analyst ratings. With an average one-year price target of $167.5, there's a potential 16.14% upside.

We recently published a list of 8 Most Promising Medical Stocks According to Hedge Funds. In this article, we are going to ...

The healthcare sector depends on medical technology advancements, particularly devices used in disease prevention, diagnosis, ...

These are independent reviews of the products mentioned, but TIME receives a commission when purchases are made through ...

Masimo MASI2.83%increase; green up pointing triangle said Joe Kiani, who previously informed the board of his decision to resign as chief executive, has been terminated by the company. Kiani’s ...

The company's financial health appears mixed. While Masimo's revenue for the last twelve months as of Q2 2024 was $2.02 billion, it experienced a revenue decline of 7.76% over the same period.